Largest effect sizes seen for diuretics and calcium channel blockers, smallest for ACE inhibitors, β-blockers
FRIDAY, May 24, 2024 (HealthDay News) — Antihypertensive drugs are associated with an increased risk for eczematous dermatitis in older adults, and the effect sizes are largest for diuretics and calcium channel blockers, according to a study published online May 22 in JAMA Dermatology.
Morgan Ye, M.P.H., from the University of California in San Francisco, and colleagues examined whether antihypertensive drug use is associated with eczematous dermatitis in a longitudinal cohort study of individuals aged 60 years and older without eczematous dermatitis at baseline.
The researchers found that the overall prevalence of eczematous dermatitis was 6.7 percent among 1,561,358 older adults during a median follow-up of six years. The incidence of eczematous dermatitis was higher among those receiving versus those not receiving antihypertensive drugs (12 versus 9 of 1,000 person-years of follow-up). Participants who received any antihypertensive drugs had a significantly increased risk for any eczematous dermatitis in adjusted analyses (hazard ratio, 1.29). When assessing each antihypertensive drug class individually, the largest effect sizes were seen for diuretics and calcium channel blockers, while the effect sizes were smallest for angiotensin-converting enzyme inhibitors and β-blockers (hazard ratios, 1.21, 1.16, 1.02, and 1.04, respectively).
“Although additional research is needed to understand the mechanisms underlying the association of antihypertensive drug use and eczematous dermatitis, these data could be helpful to clinicians to guide clinical management when an older patient presents with eczematous dermatitis,” the authors write.
Two authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Onset of Mortality, Morbidity Delayed for Offspring of Centenarians
Antenatal Complications Increased With Maternal Multiple Long-Term Conditions
Paternal Exposure to Valproate Not Linked to Offspring Neurodevelopmental Disorders
Drug Retention in Spondyloarthritis Varies With Socioeconomic Status
Timing of JAK Initiation, Shingles Vaccine Administration Can Affect Outcomes in RA
Bimekizumab Well Tolerated, Efficacious Over Three Years in Axial Spondyloarthritis
Longer Persistence Seen With Upadacitinib Versus TNFi in Rheumatoid Arthritis
Achieving Low Serum Urate Levels Can Cut Risk for Cardiovascular Events in Gout